Gyroscope Therapeutics is a clinical-stage retinal gene therapy company developing gene therapy beyond rare disease to treat a leading cause of blindness, dry age-related macular degeneration (AMD). Gyroscope is headquartered in London with locations in Philadelphia and San Francisco.